2-甲基-3-乙酰氧基苯甲酸置于盐酸,1-羟基苯并三唑,盐酸-N-乙基-N'-(3-二甲氨基丙基)碳二亚胺,三乙胺,对甲苯磺酰氯体系中,用 甲醇 用作溶剂,化学反应 3.0H,反应生成奈非那韦 参考文献:A Short Synthesis Of The Hiv-Protease Inhibitor Nelfinavir Via A Diastereoselective Addition Of Ammonia To The α,β-Unsaturated Sulfoxide Derived From ( R )-Glyceraldehyde Acetonide 标题:A Short Synthesis Of The Hiv-Protease Inhibitor Nelfinavir Via A Diastereoselective Addition Of Ammonia To The α,β-Unsaturated Sulfoxide Derived From ( R )-Glyceraldehyde Acetonide 摘要:Diastereoselective Michael Addition Of Ammonia To Sulfoxide 3A Derived From (R)-Glyceraldehyde Acetonide Provides Amine 4A,Which Is Converted Into Nelfinavir Using (Bf3Et2O)-Et-./nal Reduction And Subsequent Coupling Reactions As Key Steps. (C) 2002 Elsevier Science Ltd. All Rights Reserved. Doi:10.1016/s0040-4039(02)02077-4
专利号:US-7173059-B2 优先权日:2003-05-08 标题:Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same 发明人:ALBIZATI KIM FRANCIS; BABU SRINIVASAN 权利人:AGOURON PHARMA 摘要:Optically active 3-amino-butene and 1,2-dihydroxy-3-amino-butane intermediate compounds, useful in the synthesis of HIV-protease inhibitors and methods of preparing these intermediate compounds are disclosed.
专利号:US-6472534-B2 优先权日:1999-10-21 标 题:Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors 发明人:BORER BENNETT C; ZOOK SCOTT E; BUSSE JULIETTE K 权利人:AGOURON PHARMA 摘要:Methods for the preparation of chemical intermediates in the synthesis of HIV-protease inhibitors related to and including nelfinavir mesylate are disclosed. The method of this invention comprises converting tetrohydran derivatives into oxazolines to provide key reaction intermediates for the preparation of nelfinavir. Also disclosed is a method for the preparation of a chiral amino alcohol from an epoxy-tetrahydrofuran.
专利号:US-8987493-B2 优先权日:2010-05-20 标题 :Process for synthesis of silane dipeptide analogs 发明人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN 权利人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN; Temple University—Of the Commonwealth System of Higher Education 摘要:The invention provides a method of preparing silane dipeptide analogs, comprising the steps of treating a solution of a substituted 1,2-oxasilolane with lithium metal to form a solution of the dilithium salt of a substituted 3-hydroxypropylsilanol, and reacting the solution of the dilithium salt of the substituted 3-hydroxypropylsilanol with a substituted enamine.
专利号:US-2010261876-A1 优先权日:2007-09-25 标 题:Novel methods of synthesis for therapeutic antiviral peptides 发明人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E 权利人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E 摘要:Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
专利号:US-2025206743-A1 优先权日:2022-03-25 标 题:Tyk2 inhibitor synthesis and intermediates thereof 发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG 权利人:TAKEDA PHARMACEUTICALS CO 摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
专利号:US-11845970-B2 优先权日:2016-01-15 标 题:Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins 发明人:WANG LAI-XI; YANG QIANG; LI TIEZHENG; TONG XIN 权利人:UNIV MARYLAND 摘要:The present invention provides for recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.
1: Nagao Y, Hisanaga T, Utsumi T, Egami H, Kawato Y, Hamashima Y. Enantioselective Synthesis of Nelfinavir via Asymmetric Bromocyclization of Bisallylic Amide. J Org Chem. 2018 Mar 1. doi: 10.1021/acs.joc.8b00039. [Epub ahead of print] doi: 10.1002/art.40326. Epub 2017 Dec 8. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5. 5: Sato A, Asano T, Okubo K, Isono M, Asano T. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress. Oncol Res. 2018 Mar 5;26(2):323-332. doi: 10.3727/096504017X14957929842972. Epub 2017 May 26. doi: 10.2147/OTT.S136484. eCollection 2017. 7: Dunlop EA, Johnson CE, Wiltshire M, Errington RJ, Tee AR. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells. Oncotarget. 2017 Jul 25;8(30):48711-48724. doi: 10.18632/oncotarget.16232.
合成参考文献
参考文献:10.2165/11319380-000000000-00000 摘要:Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010 Mar 01;33(3):171–87. doi: 10.2165/11319380-000000000-00000. 参考文献:10.4103/0971-6866.80354 摘要:Shankarkumar U, Shankarkumar A, Ghosh K. Human immunodeficiency virus therapeutics and pharmacogenomics. Indian J Hum Genet. 2011 May;17 Suppl 1():S22–6. 参考文献:10.2174/1874613601105010059 摘要:Álvarez Díaz H, Mariño Callejo A, García Rodríguez JF. Non-Cirrhotic Portal Hypertension in Human Immunodeficiency Virus-Infected Patients: A New Challenge in Antiretroviral Therapy Era. TOAIDJ. 2011 Jun 29;05(1):59–61. doi: 10.2174/1874613601105010059. 参考文献:10.2174/156800911796798913 摘要:Bruning A, Vogel M, Mylonas I, Friese K, Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets. 2011 Sep;11(7):799–809. doi: 10.2174/156800911796798913. 参考文献:10.1097/qai.0b013e31822b4edc 摘要:Ellis GM, Huang S, Hitti J, Frenkel LM; P1022 Study Team. Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr. 2011 Nov 01;58(3):241–7.